Quick Facts

• May help manage discomfort and functional signs associated with venous insufficiency.
• May be used to assist in the management of symptoms related to hemorrhoidal crisis.
• Can be used to address feelings of heaviness in the lower limbs and associated pain.

Cyclo 3 fort is indicated for the management of symptoms linked to certain circulation disorders, primarily involving the lower limbs. The preparation may be used to address the feeling of heaviness in the lower limbs and related discomfort, which are characteristic of venous insufficiency. It is also utilized as an adjunct treatment for functional signs that occur during a hemorrhoidal crisis.

This medication has properties that support the tone of venous walls and improve the resistance of small blood vessels. The use of this preparation is generally integrated with advice on maintaining a healthy lifestyle, such as avoiding prolonged standing and reducing heat exposure.

Cyclo 3 fort is indicated for use in adults for the symptomatic treatment of disorders related to venous or lymphatic circulation (such as heavy legs and pain), and as an auxiliary treatment for hemorrhoidal attacks.

Contraindications

The medication should not be used in the following circumstances:

• Hypersensitivity or allergy to the active substances (Ruscus extract, Hesperidin methyl chalcone, and Ascorbic acid/Vitamin C) or any of the excipients.
• Individuals with disorders of iron storage, such as hemochromatosis, thalassemia, or sideroblastic anemia, due to the presence of Ascorbic acid (Vitamin C).

Special Populations and Considerations

Patients experiencing diarrhea should discontinue treatment immediately and consult their doctor. The drug is intended for short-term use in hemorrhoidal attacks.

Cyclo 3 fort Interactions with Other Medicines and Products

The interaction profile of Cyclo 3 fort, which contains Ruscus aculeatus extract, Hesperidin methyl chalcone, and Ascorbic acid (Vitamin C), is primarily defined by the properties of its vitamin component, as documented in official regulatory sources.

Documented Interaction Cautions

Official Regulatory Context

Co-administration with iron chelators requires strict monitoring and adherence to specific administration sequencing, particularly for patients with underlying chronic iron storage disorders, where the risk of adverse cardiac effects is heightened. This sequencing mandates that the initiation of Ascorbic acid must follow the start of Deferoxamine treatment. Furthermore, patients undergoing lab work should be aware that the medication can affect the accuracy of results for several common biological tests. Regulatory information does not document any specific metabolic (CYP), transporter, or food/alcohol interactions for the fixed-dose combination.

The mechanism of action of Cyclo 3 fort primarily involves pharmacodynamic effects on the vascular system. The Ruscus aculeatus extract components act as agonists, targeting the alpha1- and alpha2-adrenergic receptors located on venous smooth muscle cells. This interaction promotes the release of the endogenous neurotransmitter norepinephrine from presynaptic nerve endings, which subsequently activates these post-junctional alpha-adrenergic receptors. This cascade increases intracellular calcium ion ( Ca^2+) concentration, triggering the contraction of the venous smooth muscle layer. This results in an increase in venous tone and a reduction in venous capacitance. Simultaneously, the components, including hesperidin methyl chalcone and ascorbic acid, exert a stabilizing effect on the microvasculature. This action involves the inhibition of capillary permeability and protection of the endothelium, which collectively modulates the fluid dynamics and inflammatory mediators within the microcirculation.

How to Use Cyclo 3 fort

This section describes the administration principles for Cyclo 3 fort, detailing the usage patterns and dose regimens. This information is strictly procedural and does not include therapeutic claims or safety guidance.

Official Usage Patterns

Standard Dosing and Frequency

The daily dose is contingent upon the condition being addressed and is intended to be taken in divided doses (typically morning and evening):

Administration Context and Duration

The capsule must be swallowed whole with a glass of water. In the event of temporary stomach discomfort or nausea, the product should be taken at the start of a meal as a conditional adjustment. Due to the presence of Ascorbic acid, administration is generally advised to be limited to the daytime, avoiding doses after 4 p.m.

Use is indicated for adults only. For acute hemorrhoidal symptoms, the usage period is generally restricted to no more than one week. For persistent venous discomfort, a re-evaluation of treatment is advised if symptoms have not improved after 15 days of following the regimen.

Research Evidence / Overview of Studies for Cyclo 3 fort

Evidence for Symptoms of Venous Insufficiency and Circulation Discomfort

This section will summarize the structure of clinical research, including Randomized Controlled Trials (RCTs) and meta-analyses, that have investigated how symptoms like heaviness in the legs and associated edema/swelling were measured during the study period. It will outline the types of outcomes measured in these studies (e.g., changes in subjective discomfort and objective limb size).

Clinical research for this preparation was evaluated in adults experiencing the symptoms of chronic venous insufficiency (CVI), a condition where symptoms may vary in intensity. The research examined short- to intermediate-term Randomized Controlled Trials (RCTs), where groups receiving the combination drug were observed alongside groups receiving a placebo (an inactive substance) or another reference treatment. Research explored both patient-reported outcomes describing perceived discomfort and objective physical measurements.

The findings describe patterns observed in the studies over the course of the treatment period. Researchers reported how symptoms evolved in the observed populations. Studies also monitored changes in objective measures, such as variability in the size of the lower limbs, using measurements of calf and ankle circumference. This evidence contributes to the broader evidence landscape regarding how these symptoms are measured and change over time.

Evidence for Acute Hemorrhoidal Crisis

This part of the overview will describe the research base, primarily comprising short-term RCTs and systematic reviews, that has examined the use of the preparation as an adjunct treatment for the functional signs that occur during an acute hemorrhoidal flare-up.

The research exploring this use case was evaluated in adult populations during an episode where symptoms become more noticeable. Since hemorrhoids are conditions involving periods of heightened symptoms, the research focused on outcomes describing episodic or acute changes. Studies monitored the impact on outcomes related to physical discomfort, such as pain and swelling, during the short duration of the crisis. The available evidence provides insight into short-term changes relevant in evidence describing how symptoms are measured during periods of increased symptom activity.

Study Design: Comparison Groups and Measurement

This section will detail how the clinical trials were structured, including whether the medicine was studied against a placebo or other comparator agents, and the specific scales or methods researchers used to measure changes in symptoms and objective signs during the trials.

In the CVI research, this combination was studied for how the observed population’s outcomes evolved relative to groups receiving a placebo. Research also explored its outcomes when observed in trials compared directly to other compounds was studied for. The outcomes relevant in evidence describing how symptoms are measured included validated patient surveys and physical measurements.

Research Gaps and Uncertainty in the Evidence

This final section will synthesize the acknowledged limitations in the current research record, including areas where regulatory and scientific bodies have noted the need for more study, such as data consistency, sample size, or the lack of long-term tracking.

Scientific reviews indicate that the evidence quality varies across studies, particularly when examining older trial data that may have had sample sizes that were modest compared to modern trials. Furthermore, comparative evidence is lacking for direct head-to-head comparisons against all other available phlebotonic therapies, which is a research limitation frame. The evidence highlights what is known — and what is still uncertain. Research on long-term outcomes is not fully established, and the certainty remains low for long-term outcomes or use in populations outside those explicitly observed in the primary clinical trials.

Common questions about Cyclo 3 fort (FAQ)

Q: Is Cyclo 3 fort considered a herbal supplement or a pharmaceutical drug?

Official labeling describes Cyclo 3 fort as an OTC medicine or medicinal product classified as a phlebotropic agent (a type of drug that affects vein elasticity). It is a fixed-dose combination product that includes a plant extract, a semi-synthetic derivative, and a vitamin, which is how its composition is officially defined.

Q: Does Cyclo 3 fort have different brand names in other countries?

Products with the same fixed-dose combination of active ingredients as Cyclo 3 fort are sometimes sold under different brand names in various international markets. These products are often described as alternatives with the identical composition in those regions.

Q: Is Cyclo 3 fort meant for short-term use or long-term management?

Regulatory documents describe usage in terms of time limits based on the condition being addressed. For acute hemorrhoidal symptoms, the product is intended for short-term use (no more than one week). For venous circulation disorders, re-evaluation of treatment is advised if symptoms have not improved after 15 days of following the regimen.

Q: Is there a generic version of Cyclo 3 fort available?

While the specific brand name Cyclo 3 fort is protected, products that contain the same fixed-dose combination of active ingredients are available under different names in various markets. These equivalent products are sometimes described as having the same composition or as alternatives.

Q: What is the difference between Cyclo 3 fort and other similar venotonic drugs?

Official information describes Cyclo 3 fort as being distinguished by its fixed-dose combination of three active ingredients: Ruscus extract, Hesperidin methyl chalcone, and Ascorbic acid. This triad provides a combined venoconstrictor, capillary-stabilizing, and antioxidant effect, which contributes to the product’s specific pharmacological profile.

Q: Can Cyclo 3 fort cause stomach upset or digestive issues?

Yes, official safety data indicates that gastrointestinal disorders are among the most frequently reported adverse reactions. These commonly reported issues include diarrhea (sometimes severe), dyspepsia, and abdominal pain.

Q: Does alcohol consumption affect the safety or effectiveness of Cyclo 3 fort?

Regulatory information for the fixed-dose combination does not document any specific interaction between the medicine and alcohol consumption. The official documents recommend adherence to the standard administration conditions.

Q: Can Cyclo 3 fort affect liver enzyme levels?

Regulatory safety data lists elevated Alanine Aminotransferase (ALT), which is a liver enzyme, as a rare adverse reaction. This means it has been reported in a small proportion of users (less than 1 in 10,000).

Q: Does Cyclo 3 fort have any impact on weight?

Official documentation does not indicate that the product has a direct effect on weight. However, regulatory safety documents note that in rare cases, severe diarrhea (a potential side effect) may indirectly lead to weight loss and fluid/electrolyte loss if treatment is not discontinued.

Q: What is the shelf life of Cyclo 3 fort?

The medication should not be used after the expiry date (EXP), which is officially stated on the carton or primary packaging. The expiry date refers to the last day of the month indicated on the label.

Q: Is it safe to drive while taking Cyclo 3 fort?

There is no specific warning in official documents stating the product affects the ability to drive or operate machinery. However, dizziness and nervousness are listed as rare side effects; individuals who experience these effects are often advised to exercise caution.

Q: Are there restrictions on consuming certain foods while taking Cyclo 3 fort?

Official regulatory information does not document any specific restrictions on consuming foods while taking this product. The medication can be taken at the start of a meal as a conditional adjustment if stomach discomfort occurs.

Q: Does Cyclo 3 fort contain lactose or gluten?

According to the official list of excipients in the regulatory documents for the hard capsule formulation, the product does not include lactose or gluten.

Q: Can taking Cyclo 3 fort lead to skin reactions or rash?

Yes, regulatory safety data mentions the possibility of skin reactions, including maculopapular rash and urticaria (hives). However, the official frequency of these specific reactions is listed as unknown.

Q: Is there any indication that Cyclo 3 fort can affect sleep?

Regulatory safety data lists insomnia (difficulty sleeping) as an uncommon side effect. This falls into the 'uncommon' category of adverse reactions described in the safety profile.

Q: Can Cyclo 3 fort cause changes in mood?

Official safety documents list nervousness as a rare adverse reaction (occurring in less than 1 in 10,000 users). Nervousness is listed in the official safety profile as a rare adverse reaction that may affect mood.

Q: Is Cyclo 3 fort available as a cream or only as capsules/tablets?

Regulatory information and labeling identify the product only as a hard capsule intended for oral use. No other formulation, such as a cream or external preparation, is addressed in the official product information.

Q: If a person forgets to take a dose, what is the generally described procedure?

The specific product documentation does not provide instructions for a missed dose. However, standard authoritative health guidance generally indicates that a double dose should not be taken to make up for a forgotten dose.

How to Store and Dispose of Cyclo 3 fort

The storage and disposal of Cyclo 3 fort must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

The capsules must be stored at a temperature below 25°C (77°F). It is mandatory to store the medicine in its original container to protect it from environmental exposure. Crucially, the product must always be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Cyclo 3 fort must not be disposed of in wastewater (e.g., sink or toilet) or in regular household waste. The proper method is to return the medicine to a pharmacist or use a designated collection point, following all local pharmaceutical waste regulations.